Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IMTXW 
immatics biotechnologies GmbH (IMTXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/17/2025: IMTXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.05% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 673.00M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.82 | 52 Weeks Range 0.01 - 0.03 | Updated Date 05/20/2025 |
52 Weeks Range 0.01 - 0.03 | Updated Date 05/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.54% | Operating Margin (TTM) -190.37% |
Management Effectiveness
Return on Assets (TTM) -5.84% | Return on Equity (TTM) -4.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 58786524 |
Shares Outstanding - | Shares Floating 58786524 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
immatics biotechnologies GmbH
Company Overview
History and Background
Immatics Biotechnologies GmbH, founded in 2000 in Tu00fcbingen, Germany, is a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing novel T cell receptor (TCR)-based immunotherapies for the treatment of cancer. Initially focused on target discovery, it evolved to developing proprietary TCR platforms.
Core Business Areas
- Adoptive Cell Therapies (ACT): Development of cell therapies using the patient's own T cells genetically engineered to target cancer cells. Includes ACTengineu00ae and ACTallou00ae programs.
- Antibody-Like TCR Bispecifics: Development of TCR-based bispecific molecules that redirect T cells to target cancer cells. Includes TCERu00ae platform.
- Target Discovery: Identifying and validating novel cancer targets for immunotherapy development.
Leadership and Structure
The leadership team includes Carsten Reinhardt (Chairman), Steffen Diehl (Chief Development Officer), and Arnd Christ (Chief Financial Officer). The company has a board of directors and operates with functional departments across research, development, manufacturing, and commercial activities.
Top Products and Market Share
Key Offerings
- IMA203 (ACTengineu00ae):: Adoptive cell therapy targeting PRAME. Currently in clinical development for solid tumors. No current market share as it's in clinical trials. Competitors include companies developing cell therapies targeting PRAME and other solid tumor targets.
- TCERu00ae Bispecifics Platform: Proprietary platform for developing TCR-based bispecific molecules. No direct market share as it's a platform. Enables the creation of multiple product candidates. Competitors are companies with similar bispecific T cell engager platforms.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by advancements in cell therapy, antibody engineering, and target identification. The field is characterized by intense competition and high innovation rates.
Positioning
Immatics is positioned as a leader in TCR-based immunotherapies, focusing on addressing unmet needs in solid tumors. Its competitive advantages include proprietary TCR platforms and expertise in target discovery.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapy is estimated to be hundreds of billions of dollars. Immatics is positioned to capture a portion of this TAM with its innovative TCR-based therapies targeting solid tumors. Exact value fluctuates with market predictions.
Upturn SWOT Analysis
Strengths
- Proprietary TCR technology platforms (ACTengineu00ae, TCERu00ae)
- Expertise in target discovery
- Clinical-stage pipeline with multiple product candidates
- Strong partnerships with leading pharmaceutical companies
Weaknesses
- High R&D costs associated with drug development
- Clinical trial risk and regulatory hurdles
- Competition from larger pharmaceutical companies
- Dependence on funding and partnerships
Opportunities
- Expanding pipeline with new TCR-based therapies
- Partnering with pharmaceutical companies for commercialization
- Entering new markets and indications
- Advancing personalized cancer immunotherapies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from new technologies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- NKX
- MRTX
- BMRN
Competitive Landscape
Immatics' advantages include its proprietary TCR platforms and expertise in target discovery. Disadvantages include competition from larger pharmaceutical companies with greater resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historically, Immatics has grown through strategic partnerships, clinical trial advancements, and expansion of its technology platforms.
Future Projections: Future growth is projected to be driven by clinical trial successes, regulatory approvals, and commercialization of its TCR-based therapies. Analyst estimates vary depending on clinical data and market conditions.
Recent Initiatives: Recent initiatives include advancing clinical trials for IMA203 and other product candidates, expanding its TCR discovery platform, and forging new partnerships with pharmaceutical companies.
Summary
Immatics is a clinical-stage biopharmaceutical company with promising TCR-based immunotherapy platforms. Its strengths lie in its innovative technology and partnerships, but it faces risks related to clinical trials, competition, and funding. Advancing clinical programs and successful commercialization are crucial for future growth. The company needs to be aggressive in developing its product line and look for acquisitions to grow its overall offering and stay relevant.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and represents an opinion. It is not financial advice. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About immatics biotechnologies GmbH
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-07-02 | CEO, MD, Member of Management Board & Executive Director Dr. Harpreet Singh Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 646 | Website https://www.immatics.com |
Full time employees 646 | Website https://www.immatics.com | ||
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.